ATLANTA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Global Genomics Group (G3), a life sciences company that leverages large-scale genomic and molecular disease profiles to develop life-changing diagnostics and therapeutics, and GNS Healthcare(GNS), a leading precision medicine company that applies causal machine learning technology to match health interventions to individual patients and discover new target intervention pathways, today announced preliminary results of the GLOBAL Clinical Study designed to identify biomarkers associated with coronary artery disease (CAD). The study provided proof of concept of the approach by prospectively identifying a biochemical pathway known to be associated with CAD.
Read the full article here:
News